

1	2	3
11.	Nagaland	20
12.	Odisha	30
13.	Rajasthan	20
14.	Sikkim	10
15.	Tripura	10
16.	Uttar Pradesh	20

**Fostering development of Ayurveda**

†2568. DR. BHUSHAN LAL JANGDE : Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) whether Ayurveda has been ignored by the Central Government;
- (b) whether the Central Government proposes to create a separate Department and Ministry for Ayurveda;
- (c) if so, by when and, if not, the reasons therefor;
- (d) the reasons for the Central Government not being much enthusiastic towards development of Ayurveda in spite of this country being original source of Ayurveda and the whole world is looking upto it;
- (e) whether Government contemplates planting herbs and medicinal plants after identifying the hilly and forest areas; having reserves for the same and where deforestation is taking place at large; and
- (f) whether Government proposes to expand the areas of herbal gardens?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI S. GANDHISELVAN) : (a) No.

(b) to (d) Department of Indian Systems of Medicine & Homoeopathy (ISM&H) was established as separate Department in March, 1995. It was re-named as Department

---

† Original notice of the question was received in Hindi.

of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) in November, 2003. The Department is responsible for policy formulation, development and implementation of programmes for the growth, development and propagation of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) systems of Health Care. Sowa Rigpa is the recent addition to the existing family of AYUSH systems. The Department has been able to promote Ayurveda in India and abroad with focused attention. The physical and financial progress under Ayurveda over the years is given below:

*Physical*

Sl.No.	Scheme	As on	
		1980	2011
1.	Hospitals	252	2420
2.	Registered Practitioners	220497	429246

*Financial*

(Rs. in crores)

	Expenditure
8th Plan (1992-97)	26.53
9th Plan (1997-2002)	62.18
10th Plan (2002-2007)	102.77
11th Plan (2007-2012)	431.75
2012-13	152.27*

\*Allocation for 2012-13.

(e) and (f) The National Medicinal Plants Board under Department of AYUSH has been implementing a Central Sector Scheme for “Conservation, Development and Sustainable Management of Medicinal Plants” to provide support for Survey, Inventorisation and in-situ conservation, ex-situ conservation / herbal garden, linkage with JFMCs, Research and Development, Establishing quality standards and

certification, capacity building, etc. Under this scheme the financial support is being also provided for planting herbs and medicinal plants in identified hilly and forests areas. Under the Scheme for Reforestation/Conservation/Resource Augmentation of Medicinal Plants over 46,121.50 hectares in Forest Areas have been covered till 31st July, 2012 as per details below:

- (i) 25,549.00 hectares under Resource Augmentation;
- (ii) 12,727.50 hectares under in-situ Conservation; and
- (iii) 7,845 hectares under Medicinal Plants Conservation Areas (40 in numbers).

Besides herbal garden have been established in 1819.57 hectare area in different parts of the country.

#### **Sale of banned drugs**

†2569. SHRI KAPTAN SINGH SOLANKI : Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) whether it is a fact that the medicines which are banned abroad are being sold openly in our country;
- (b) if so, the details thereof;
- (c) whether it is being carried out in collusion with drugs controller organisations and drug manufacturers;
- (d) if so, whether Government has received any complaint in this regard; and
- (e) if so, the details thereof?

THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABIAZAD) : (a) to (e) A drug banned/restricted in one country may continue to be marketed in other countries as the respective government examines the usage, doses, indications permitted etc. and overall risk benefits ratio and take decisions on the continued marketing of any drug in that country.

Safety issues of drug formulations, as and when reported are assessed in consultation with the Expert Committee/Drugs Technical Advisory Board (DTAB).

---

† Original notice of the question was received in Hindi.